Dr. Jose Gilberto Bazan Jr., MD

Dr. Bazan practices at City of Hope Comprehensive Cancer Center - Duarte in Duarte, California.

Dr. Bazan's NPI, 1851535504, was assigned on April 25, 2009. Dr. Bazan graduated from Stanford University School Of Medicine in 2008. Dr. Bazan holds California license A110291.

Dr. Bazan's primary practice is City of Hope Comprehensive Cancer Center - Duarte, at 1500 Duarte Rd, Duarte, CA 91010 in Los Angeles County. The practice phone is (800) 826-4673.

Dr. Bazan's primary practice is City of Hope Comprehensive Cancer Center - Duarte in Duarte, California. The medical group on file is City of Hope. Dmand AI also links Dr. Bazan to 1 more other site, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Bazan practices. Vendor and product names are available with a free account.

Radiation oncology is Dr. Bazan's primary specialty in the NPI Registry, under taxonomy code 2085R0001X. Dr. Bazan is board certified in radiation oncology by the American Board of Radiology. Dmand AI has Dr. Bazan's licenses on file in 2 states: California and Ohio.

Dmand AI lists anal cancer radiation, bladder cancer radiation, bone cancer radiation, brain cancer radiation and breast cancer radiation among the conditions Dr. Bazan treats.

CMS data shows 1,175 Medicare services from Dr. Bazan across 12 procedure codes in 2024, for 136 Medicare patients. Medicare paid $86,755 for them.

CMS counts 136 Medicare patients who saw Dr. Bazan in 2024. The largest group is 65 to 74, with 67 patients. 75% of them have cancer, and 74% have high cholesterol. 39% are also on Medicaid. Their average risk score is 1.93, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Bazan's median patient age at 65, with 98% women.

In 2024, Dr. Bazan wrote 47 Medicare Part D claims for 24 patients. 89% of them were for generic drugs. CMS names the drug for 11 of them, across 1 drug with 11 or more claims each, at $60 in total drug cost. In 2022, CMS named 17 claims across 1 drug.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 93 out of 100 for Dr. Bazan for performance year 2024, reported as part of a group. Dr. Bazan accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Bazan as offering telehealth.

Dmand AI links 69 papers to Dr. Bazan, published from 2011 to 2025. 2023 was the busiest year, with 9. The most frequent topics are Breast Neoplasms, Lung Neoplasms and Mastectomy. Dr. Bazan has published most often in Int J Radiat Oncol Biol Phys. Dr. Bazan's most frequent co-authors are Sachin Jhawar, MD, MS, Terence Williams, MD and Sasha J. Beyer.

Dmand AI links Dr. Bazan to 2 clinical trials. 2 are still active or recruiting. Conditions studied include Breast Neoplasms and Breast Diseases. Ohio State University Comprehensive Cancer Center sponsors the most, 2.

CMS Open Payments shows 3 general payments to Dr. Bazan from 1 drug or device company from 2023 to 2025. Food and beverage make up the largest share, 100% of the total. GE Healthcare paid the most, $291.

Dmand AI lists 1 award for Dr. Bazan, most recently CMS Stage 1 EHR in 2013.

Dr. Bazan graduated from Stanford University School Of Medicine in 2008.

Dr. Bazan is in network with 13 carriers, including Aetna, Elevance and Blue Cross Blue Shield of Michigan. Medicare plans come from the most carriers, 9. Check the plan with the practice before a visit.